Here are the Form 4 insider transactions from BeOne Medicines Ltd. (ONC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ONC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONC filings page.
BeOne Medicines Ltd. insiders linked to Baker Bros. entities reported small share sales tied to RSU vesting and tax withholding. On May 22, 2026, Michael Goller sold 2,743 ordinary shares at $23.8512 per share and Ranjeev Krishana sold 2,756 ordinary shares at $23.7905 per share. Footnotes explain these 5,499 ordinary shares, in the form of 423 American Depositary Shares (ADS), were sold in connection with the vesting of restricted stock units as mandatory tax-withholding transactions, not discretionary open-market selling. The positions are attributed to funds advised by Baker Bros. Advisors LP, which has voting and dispositive power, while Julian and Felix Baker and related entities disclaim beneficial ownership beyond their indirect pecuniary interest. After these transactions, the funds continue to hold large positions, including 8,068,411 ADS and 730,642 ADS reported as indirect holdings.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised employee share options covering 4,316 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96 per share. The options were represented as Share Options (Right to Buy) and convert into Ordinary Shares.
On the same date, he sold 332 American Depositary Shares at an average price of $310.72 per ADS in an open-market transaction made under a Rule 10b5-1 trading plan. Following these transactions, he directly owns 318,370 Ordinary Shares and no American Depositary Shares.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. reported that Chief Financial Officer Aaron Rosenberg received equity compensation in the form of ordinary shares linked to performance share units. On March 6, 2026, he was granted 79,014 ordinary shares underlying earned performance share units that are scheduled to vest in 2027, and an additional 40,573 ordinary shares underlying earned performance share units scheduled to vest in 2028.
All of these earned performance share units will vest only if Rosenberg continues to provide service to the company through the respective vesting dates, with unvested awards eligible for accelerated vesting upon certain termination events. Following these awards, his direct ownership increased to 334,919 ordinary shares, reflecting a compensation-related acquisition rather than an open-market purchase.
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry reported option exercises and share sales. On 02/04/2026, Henry exercised three employee share options covering 6,526, 8,606 and 6,448 ordinary shares, which relate to American Depositary Shares (each ADS represents 13 ordinary shares).
On the same date, Henry sold 664 ADS at $348.79 and 996 ADS at $350.00 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, leaving no ADS directly held. Henry continues to directly hold 223,106 ordinary shares and significant remaining options that vest over multi-year schedules, subject to continued service and potential accelerated vesting on certain termination events.
BeOne Medicines Ltd. insider Lee Chan Henry, SVP and General Counsel, reported option exercises and an automatic sale of American Depositary Shares (ADS). On January 7, 2026, Henry exercised three share options covering 2,626, 3,458 and 2,548 Ordinary Shares at exercise prices of $14.96, $16.41 and $12.23 per Ordinary Share. These exercises resulted in issuances of 202, 266 and 196 ADS at prices of $194.47, $213.32 and $159.03 per ADS. The filing also reports a sale of 664 ADS at $331.76 per ADS, carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, Henry reported 223,106 Ordinary Shares beneficially owned directly and continued holdings of multiple option grants with staggered vesting schedules.
BeOne Medicines Ltd. reported that its President and Global Head of R&D received a large equity award in the form of restricted share units. On December 31, 2025, the executive acquired 427,895 ordinary shares at a stated price of $0, reflecting the vesting terms of these units rather than a cash purchase.
After this transaction, the executive beneficially owns 1,451,424 ordinary shares directly and 601,965 shares indirectly through Wang Holdings LLC. The filing also explains a separate RMB Shares Employee Participation Plan tied to the company’s STAR Market offering in China, under which the plan purchased 2,069,546 RMB Shares at an initial public offering price of RMB192.6 per share. The reporting person contributed RMB10 million to this plan and may have an indirect economic interest in some of these RMB Shares while disclaiming beneficial ownership except for any pecuniary interest.
BeOne Medicines Ltd. chief executive officer and director reported sales of American Depositary Shares in mid-December 2025 under a pre-arranged Rule 10b5-1 trading plan.
The Form 4 discloses multiple sales of American Depositary Shares on 12/15/2025 and 12/16/2025 at weighted average prices listed in the report, with each American Depositary Share representing 13 ordinary shares. Following these transactions, the reporting person holds 0 American Depositary Shares directly but continues to beneficially own 5,141,041 ordinary shares directly and additional ordinary shares through various trusts and entities, with certain indirect interests expressly disclaimed as beneficial ownership.
BeOne Medicines Ltd. executive SVP and General Counsel reported stock transactions in the company’s American Depositary Shares (ADSs). On December 10 and 11, 2025, the insider exercised stock options and then sold shares, as shown in the Form 4 tables. The filing shows multiple option exercises into ADSs, followed by open-market sales of 332 ADSs at $318.28 on December 10 and 332 ADSs at $325.00 on December 11.
Each ADS represents 13 ordinary shares, and the derivative securities are stock options with exercise prices of $14.96, $16.41, and $12.23 per ordinary share. The options vest over four-year schedules with initial 25% vesting and the remainder in monthly installments, with potential accelerated vesting upon certain termination events. The sale transactions were carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025.
BeOne Medicines Ltd. director reports option exercise and ADS sales. On 11/26/2025, the reporting director exercised a share option covering 34,151 ordinary shares at an exercise price of $12.23 per share. Each American Depositary Share (ADS) represents 13 ordinary shares, so the exercise resulted in 2,627 ADS at a reported price of $159.03 per ADS. On the same date, the director sold 1,823 ADS at a weighted average price of $340.2004 and 804 ADS at a weighted average price of $342.474, leaving 0 ADS beneficially owned after the transactions. Following these activities, the director reported beneficial ownership of 57,226 ordinary shares held directly.
BeOne Medicines Ltd. (ONC) reported an insider transaction by its President and COO on a Form 4. The executive is listed as directly holding 968,978 ordinary shares and indirectly holding 4,000 American Depositary Shares (ADS) through his wife. Each ADS represents 13 ordinary shares.
On 11/17/2025, the reporting person sold ADS in three open-market transactions: 3,155 ADS at a weighted average price of $380.2274, 826 ADS at a weighted average price of $381.1891, and 10 ADS at $382.32. After these sales, the Form 4 shows reduced direct ADS holdings, while the separate ordinary share and spouse-held ADS positions remain reported.
BeOne Medicines Ltd. (ONC) reported insider transactions by its President and COO. The reporting person sold 16,009 American Depositary Shares (ADS) on 11/12/2025 and 11/13/2025 at weighted average prices with trade ranges from $350.00 to $381.50, as detailed in the footnotes.
After these sales, the reporting person held 0 ADS directly. Beneficial ownership also includes 1,020,861 ordinary shares and 4,000 ADS held indirectly by spouse. Each ADS represents 13 ordinary shares. One footnote states that the ordinary share total includes 650 ordinary shares acquired under the company’s employee share purchase plan.
BeOne Medicines (ONC) reported insider activity by its SVP, General Counsel. On 11/12/2025, the officer exercised share options into 996 American Depositary Shares (ADS), which equals 12,948 Ordinary Shares (each ADS represents 13 Ordinary Shares), and sold 996 ADS pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
The ADS sales were executed at $348.75 (664 ADS) and $350 (332 ADS). Following these transactions, the reporting person beneficially owned 223,106 Ordinary Shares directly. The option exercises reflected exercise prices represented in Ordinary Shares of $14.96, $16.41, and $12.23, respectively.
BeOne Medicines (ONC) reported insider activity by its Chief Executive Officer and Director. The reporting person made two bona fide gifts of ordinary shares: 151,320 shares on 11/11/2025 and 858,533 shares on 11/12/2025, for a combined 1,009,853 shares, each at a stated price of $0 per footnote (gift). After these transactions, direct beneficial ownership stood at 6,441,041 ordinary shares.
The filing also lists indirect holdings, including 481,533 (P&O Trust), 7,722,480 (a grantor retained annuity trust), 28,204,115 (Oyler Investment LLC), 9,545,000 (Roth IRA), and 102,188 (The John Oyler Legacy Trust), as described in the footnotes with certain beneficial ownership disclaimers. No derivative securities were reported.
BeOne Medicines (ONC): A director and Chair of the Scientific Advisory Board reported a bona fide gift of 424,073 ordinary shares on 11/07/2025 (Code G) at $0 pursuant to Rule 16b-5. Following the transaction, the director beneficially owned 4,582,601 shares directly.
Additional indirect holdings were reported with a disclaimer of beneficial ownership: 1,025,063 shares via a family trust, 3,953,100 shares via Wang Investment LLC, and 50 shares held by the spouse.